[go: up one dir, main page]

NL301219I1 - - Google Patents

Info

Publication number
NL301219I1
NL301219I1 NL301219C NL301219C NL301219I1 NL 301219 I1 NL301219 I1 NL 301219I1 NL 301219 C NL301219 C NL 301219C NL 301219 C NL301219 C NL 301219C NL 301219 I1 NL301219 I1 NL 301219I1
Authority
NL
Netherlands
Application number
NL301219C
Other versions
NL301219I2 (nl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56740579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301219(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NL301219I1 publication Critical patent/NL301219I1/nl
Publication of NL301219I2 publication Critical patent/NL301219I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL301219C 2015-08-17 2023-02-22 teclistamab NL301219I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206246P 2015-08-17 2015-08-17
PCT/US2016/047146 WO2017031104A1 (en) 2015-08-17 2016-08-16 Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof

Publications (2)

Publication Number Publication Date
NL301219I1 true NL301219I1 (nl) 2023-03-01
NL301219I2 NL301219I2 (nl) 2023-04-04

Family

ID=56740579

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301219C NL301219I2 (nl) 2015-08-17 2023-02-22 teclistamab

Country Status (41)

Country Link
US (1) US10072088B2 (nl)
EP (3) EP3757131A1 (nl)
JP (4) JP2018525005A (nl)
KR (2) KR102890745B1 (nl)
CN (1) CN108350076B (nl)
AR (2) AR105724A1 (nl)
AU (1) AU2016308567B2 (nl)
BR (1) BR112018003017A2 (nl)
CA (1) CA2995754A1 (nl)
CL (1) CL2018000431A1 (nl)
CO (1) CO2018001524A2 (nl)
CY (2) CY1123297T1 (nl)
DK (1) DK3337824T3 (nl)
EA (1) EA201890513A1 (nl)
EC (1) ECSP18019568A (nl)
ES (1) ES2814550T3 (nl)
FI (1) FIC20230012I1 (nl)
FR (2) FR23C1011I1 (nl)
HR (1) HRP20201375T1 (nl)
HU (2) HUE050556T2 (nl)
IL (3) IL298041B2 (nl)
JO (1) JO3799B1 (nl)
LT (2) LT3337824T (nl)
LU (1) LUC00301I2 (nl)
MA (1) MA53750A (nl)
MX (2) MX2018002043A (nl)
MY (1) MY191325A (nl)
NI (1) NI201800027A (nl)
NL (1) NL301219I2 (nl)
PE (1) PE20180795A1 (nl)
PH (1) PH12018500361A1 (nl)
PL (1) PL3337824T3 (nl)
PT (1) PT3337824T (nl)
RS (1) RS60755B1 (nl)
SI (1) SI3337824T1 (nl)
SV (1) SV2018005634A (nl)
TW (3) TW202406935A (nl)
UA (1) UA127515C2 (nl)
UY (2) UY36859A (nl)
WO (1) WO2017031104A1 (nl)
ZA (1) ZA201801789B (nl)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
EP3172237A2 (en) 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using humanized anti-bcma chimeric antigen receptor
BR112017024899A2 (pt) 2015-05-21 2018-11-13 Harpoon Therapeutics, Inc. proteínas de ligação trispecíficas e métodos de uso.
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
HUE050556T2 (hu) * 2015-08-17 2020-12-28 Janssen Pharmaceutica Nv Anti-BCMA ellenanyagok, BCMA-t és CD3-at kötõ bispecifikus antigénkötõ molekulák és ezek alkalmazásai
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
MA43959A (fr) 2016-02-03 2018-12-12 Amgen Res Munich Gmbh Constructions d'anticorps impliquant des cellules t bispécifiques psma et cd3
IL260732B2 (en) 2016-02-17 2024-08-01 Seagen Inc Bcma antibodies and use of same to treat cancer and immunological disorders
BR112018072211A2 (pt) * 2016-05-09 2019-02-12 Bristol-Myers Squibb Company anticorpos anti tl1a e utilizações dos mesmos
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
UA126384C2 (uk) 2016-09-14 2022-09-28 Тенеобіо, Інк. Антитіло, яке зв'язує cd3
KR20250004936A (ko) 2016-12-21 2025-01-08 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
US20190336533A1 (en) 2016-12-28 2019-11-07 Green Cross Lab Cell Corporation Chimeric antigen receptor and natural killer cells expressing same
EP3577134A1 (en) 2017-01-31 2019-12-11 Novartis AG Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2018231944A1 (en) 2017-06-13 2018-12-20 Berenson James R Diagnostic, prognostic, and monitoring methods for solid tumor cancers
WO2018237006A1 (en) * 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
KR102742528B1 (ko) 2017-06-20 2024-12-16 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
SG11202000499RA (en) * 2017-08-01 2020-02-27 Medimmune Llc Bcma monoclonal antibody-drug conjugate
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11517591B2 (en) 2017-09-01 2022-12-06 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
KR102425983B1 (ko) 2017-10-13 2022-07-29 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
JP7585034B2 (ja) 2017-10-18 2024-11-18 ノバルティス アーゲー 選択的タンパク質分解のための組成物及び方法
CN111511370A (zh) 2017-11-01 2020-08-07 朱诺治疗学股份有限公司 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
MA50564A (fr) 2017-11-06 2020-09-16 Hutchinson Fred Cancer Res Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
JP2021502979A (ja) 2017-11-15 2021-02-04 ノバルティス アーゲー Ｂｃｍａターゲティングキメラ抗原受容体、ｃｄ１９ターゲティングキメラ抗原受容体及び併用療法
KR20200096253A (ko) 2017-11-30 2020-08-11 노파르티스 아게 Bcma-표적화 키메라 항원 수용체, 및 이의 용도
US12539308B2 (en) 2018-01-08 2026-02-03 The Trustees Of The University Of Pennsylvania Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US11993658B2 (en) * 2018-03-26 2024-05-28 Sutro Biopharma, Inc. Anti-BCMA antibodies and treatment methods
SG11202010064QA (en) * 2018-04-13 2020-11-27 Affimed Gmbh Nk cell engaging antibody fusion constructs
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
JP7395508B2 (ja) * 2018-05-16 2023-12-11 ヤンセン バイオテツク，インコーポレーテツド 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法
US11492409B2 (en) * 2018-06-01 2022-11-08 Novartis Ag Binding molecules against BCMA and uses thereof
EP3806962A1 (en) 2018-06-13 2021-04-21 Novartis AG Bcma chimeric antigen receptors and uses thereof
WO2019241686A1 (en) * 2018-06-14 2019-12-19 Bluebird Bio, Inc. Anti-bcma car antibodies, conjugates, and methods of use
WO2020004934A1 (ko) * 2018-06-26 2020-01-02 에이비엘바이오 주식회사 항-bcma 항체 및 그 용도
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
TWI838389B (zh) * 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
EP3823665B1 (en) 2018-07-19 2024-01-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with bcma specificity and uses thereof
JP2021532073A (ja) * 2018-07-31 2021-11-25 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ−ｃｄ３二重特異性抗体のための投与レジメン
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3844267B1 (en) 2018-08-31 2025-06-25 Novartis AG Methods of making chimeric antigen receptor-expressing cells
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
US12116415B2 (en) 2018-10-09 2024-10-15 Single Cell Technology, Inc. Anti-BCMA antibodies
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
MX2021005155A (es) 2018-11-01 2021-09-30 Shandong New Time Pharmaceutical Co Ltd Anticuerpo biespecífico y uso del mismo.
CA3123599A1 (en) * 2018-12-19 2020-06-25 City Of Hope Baff-r bispecific t-cell engager antibody
CN113795512A (zh) * 2019-02-01 2021-12-14 葛兰素史克知识产权开发有限公司 包含贝兰他单抗莫福汀和抗ox4抗体的癌症组合治疗及其用途和方法
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CN114026122B (zh) 2019-02-21 2024-12-31 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
CA3126087A1 (en) 2019-02-25 2020-09-03 Novartis Ag Mesoporous silica particles compositions for viral delivery
MX2021010281A (es) * 2019-02-26 2021-09-23 Sorrento Therapeutics Inc Proteinas de enlace a antigenos que se enlazan al bcma.
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
PE20220142A1 (es) 2019-04-05 2022-01-27 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
EP3733707A1 (en) * 2019-04-30 2020-11-04 Celyad S.A. Car t-cells targeting bcma and uses thereof
US20220323599A1 (en) * 2019-05-03 2022-10-13 Celgene Corporation Anti-bcma antibody conjugate, compositions comprising the same, and methods of making and using the same
KR20220008866A (ko) 2019-05-14 2022-01-21 하푼 테라퓨틱스, 인크. EpCAM 결합 단백질 및 사용 방법
KR20250156861A (ko) 2019-05-21 2025-11-03 노파르티스 아게 Cd19 결합 분자 및 이의 용도
JOP20210323A1 (ar) 2019-06-14 2023-01-30 Teneobio Inc ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
CN110229232B (zh) * 2019-06-19 2020-05-19 北京智仁美博生物科技有限公司 双特异性抗体及其用途
KR20220068984A (ko) * 2019-07-30 2022-05-26 상하이 한서 바이오메디컬 컴퍼니 리미티드 항-bcma 항체, 이의 항원-결합 단편 및 이의 의학적 용도
WO2021092060A1 (en) * 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment
DK3819007T3 (da) 2019-11-11 2024-09-30 Amgen Res Munich Gmbh Doseringsplan for anti-bcma-midler
CA3163104A1 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
US11919965B2 (en) 2019-12-06 2024-03-05 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
EP4048700A4 (en) * 2019-12-10 2023-12-06 ABL Bio Inc. BISPECIFIC ANTI-BCMA/ANTI-4-1BB ANTIBODIES AND THEIR USES
WO2021132746A1 (en) * 2019-12-24 2021-07-01 Abl Bio, Inc. Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
CN114929277A (zh) * 2019-12-16 2022-08-19 2赛文缇生物公司 抗bcma car抗体、缀合物及使用方法
US20230055711A1 (en) * 2020-01-03 2023-02-23 Biosion Inc. Antibodies binding bcma and uses thereof
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
US20230256017A1 (en) 2020-02-27 2023-08-17 Jennifer Brogdon Methods of making chimeric antigen receptor-expressing cells
MX2022010685A (es) 2020-02-27 2022-09-23 Novartis Ag Metodos de produccion de celulas que expresan receptores de antigeno quimericos.
EP4118121A4 (en) * 2020-03-13 2024-05-15 Janssen Biotech, Inc. MATERIALS AND METHODS FOR MODULATING T CELL-MEDIATED IMMUNITY
TW202144425A (zh) * 2020-04-17 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 特異性抗原結合分子，其製備方法及醫藥用途
UY40003A (es) * 2020-04-29 2023-03-31 Teneobio Inc Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
MX2022013453A (es) * 2020-04-29 2022-11-16 Teneobio Inc Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas.
CN113637073B (zh) * 2020-05-11 2024-04-12 上海赛比曼生物科技有限公司 Bcma抗体及其制备和应用
AU2021272291A1 (en) 2020-05-11 2023-02-02 Janssen Biotech, Inc. Methods for treating multiple myeloma
US20210363252A1 (en) 2020-05-19 2021-11-25 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
KR20230015996A (ko) * 2020-06-30 2023-01-31 하버 바이오메드 (상하이) 컴퍼니 리미티드 H2l2 및 hcab 구조를 갖는 결합 단백질
WO2022006316A1 (en) 2020-06-30 2022-01-06 Teneobio, Inc. Multi-specific antibodies binding to bcma
CN114075287B (zh) * 2020-08-18 2023-07-21 湖南远泰生物技术有限公司 人源化bcma抗体和bcma-car-t细胞
TW202227124A (zh) 2020-08-21 2022-07-16 瑞士商諾華公司 用於體內產生ｃａｒ表現細胞的組成物和方法
MX2023003034A (es) * 2020-09-14 2023-04-10 Pfizer Metodos, terapias y usos para tratar el cancer.
WO2022060901A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
US20240002539A1 (en) * 2020-11-03 2024-01-04 Ab Studio Inc. Multispecific antibodies and uses thereof
EP4240756A1 (en) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
CN114524878B (zh) * 2020-11-23 2024-08-02 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
CN114573703A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种t细胞衔接器治疗剂的开发和应用
WO2022135468A1 (zh) * 2020-12-23 2022-06-30 信达生物制药(苏州)有限公司 抗bcma×cd3双特异性抗体及其用途
JP2024506831A (ja) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイトカイン放出症候群を治療するための組成物及び方法
JP2024507180A (ja) 2021-02-16 2024-02-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
WO2022187710A1 (en) * 2021-03-05 2022-09-09 Atreca, Inc. Epha2 antibodies
TW202304988A (zh) 2021-03-24 2023-02-01 美商健生生物科技公司 靶向ＣＤ７９ｂ、ＣＤ２０、及ＣＤ３之三特異性抗體
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
EP4330381A1 (en) 2021-04-27 2024-03-06 Novartis AG Viral vector production system
EP4329818A1 (en) 2021-04-30 2024-03-06 Celgene Corporation Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi)
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
KR20240014482A (ko) 2021-05-28 2024-02-01 얀센 바이오테크 인코포레이티드 B 세포 림프종에서 T 세포 재지향 항체에 대한 표적으로서의 Bcma
CN119569887A (zh) * 2021-06-24 2025-03-07 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
CN115569191A (zh) * 2021-07-05 2023-01-06 山东新时代药业有限公司 一种重组人源化抗bcma/cd3双特异性抗体冻干制剂
WO2023020474A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Bcma targetting antibodies and uses thereof in cancer therapies
AU2022330406A1 (en) 2021-08-20 2024-03-07 Novartis Ag Methods of making chimeric antigen receptor–expressing cells
PE20241173A1 (es) 2021-10-14 2024-05-28 Arsenal Biosciences Inc Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica
CA3237643A1 (en) * 2021-10-27 2023-05-04 Janssen Biotech, Inc. Methods for enhanced bcma immunohistochemistry detection in human and monkey tissue
EP4426437A4 (en) 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES
CA3237175A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Corticosteriod reduction in treatment with anti-cd38 antibodies
KR20240099432A (ko) * 2021-11-10 2024-06-28 얀센 바이오테크 인코포레이티드 이중특이성 bcma/cd3 항체를 포함하는 안정한 제형
JP2024541668A (ja) * 2021-12-03 2024-11-08 山▲東▼先声生物制▲薬▼有限公司 抗ｂｃｍａナノ抗体及びその応用
WO2023201226A1 (en) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN117003871A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
CN116023504B (zh) * 2022-06-07 2025-09-30 江苏蒙彼利生物科技有限公司 双特异性嵌合抗原受体（car）及其制备方法
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
JP2025537692A (ja) 2022-11-02 2025-11-20 ヤンセン バイオテツク，インコーポレーテツド 癌を治療する方法
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
KR20250143880A (ko) * 2022-12-02 2025-10-02 아티바 바이오테라퓨틱스, 인크. 항-bcma 항체 또는 그의 항원-결합 단편, 및 그를 포함하는 키메라 항원 수용체
CN117186228B (zh) * 2022-12-06 2024-03-22 成都赛恩吉诺生物科技有限公司 包含长cdr3序列的抗人bcma纳米抗体的双特异性抗体及应用
WO2024124088A1 (en) * 2022-12-09 2024-06-13 Sana Biotechnology, Inc. Bcma-specific antibody constructs and compositions thereof
CN120857940A (zh) 2023-02-17 2025-10-28 瑞泽恩制药公司 对cd3/taa双特异性抗体有反应的诱导型nk细胞
CN121263449A (zh) 2023-03-21 2026-01-02 拜格拉夫55公司 Cd19/cd38多特异性抗体
AU2024257254A1 (en) * 2023-04-19 2025-12-04 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2024231860A1 (en) 2023-05-09 2024-11-14 Janssen Biotech, Inc. Pharmaceutical compositions comprising a bispecific bcma/cd3 antibody at high concentration
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2024251154A1 (zh) 2023-06-06 2024-12-12 信达生物制药(苏州)有限公司 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025094107A1 (en) 2023-11-01 2025-05-08 Janssen Biotech, Inc. Methods for treating high-risk smoldering multiple myeloma
WO2025096717A1 (en) 2023-11-01 2025-05-08 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2025131077A1 (zh) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 抗cd3多特异性抗体及用途
WO2025160324A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025243241A1 (en) 2024-05-23 2025-11-27 Janssen Biotech, Inc. Methods for treating multiple myeloma

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
ATE294860T1 (de) 1997-09-16 2005-05-15 Egea Biosciences Llc Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
DK1940881T3 (en) 2005-10-11 2017-02-20 Amgen Res Munich Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
WO2007059782A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
KR101626988B1 (ko) 2007-04-03 2016-06-02 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 이중특이적인 결합제들
PT2520590T (pt) 2007-04-03 2018-11-14 Amgen Res Munich Gmbh Domínio de ligação específico de espécies cruzadas
CN103694350B (zh) 2007-04-03 2018-04-24 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
EP2283355A2 (en) 2008-04-25 2011-02-16 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
CA2738565C (en) 2008-10-01 2023-10-10 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
DK2352763T4 (da) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
WO2010051274A2 (en) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
BRPI1008532B1 (pt) 2009-02-12 2021-12-14 Janssen Biotech, Inc Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
MX2011009430A (es) 2009-03-10 2011-11-18 Biogen Idec Inc Anticuerpos anti-bcma.
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
ES2989108T3 (es) 2010-04-20 2024-11-25 Genmab As Proteínas que contienen FC de anticuerpos heterodiméricos y métodos para producir las mismas
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
JP2014500879A (ja) 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
AU2012289926A1 (en) * 2011-08-03 2014-03-13 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
FI3653049T3 (fi) 2012-12-14 2023-11-02 Omniab Inc Polynukleotidit, jotka koodaavat jyrsijän vasta-aineita, joissa on ihmisen idiotyyppejä, ja näitä käsittävät eläimet
CN104968682A (zh) 2013-02-05 2015-10-07 英格玛布股份公司 针对CD3ε和BCMA的双特异性抗体
EP2762497A1 (en) * 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
HUE050556T2 (hu) * 2015-08-17 2020-12-28 Janssen Pharmaceutica Nv Anti-BCMA ellenanyagok, BCMA-t és CD3-at kötõ bispecifikus antigénkötõ molekulák és ezek alkalmazásai

Also Published As

Publication number Publication date
LT3337824T (lt) 2020-09-25
ES2814550T3 (es) 2021-03-29
JP2018525005A (ja) 2018-09-06
AR134557A2 (es) 2026-01-28
TW202406935A (zh) 2024-02-16
AR105724A1 (es) 2017-11-01
FIC20230012I1 (fi) 2023-02-22
IL320478A (en) 2025-06-01
LTC3337824I2 (nl) 2024-10-25
FR23C1012I2 (fr) 2025-01-10
AU2016308567A1 (en) 2018-03-08
KR20180040671A (ko) 2018-04-20
JP2021184721A (ja) 2021-12-09
EP4667058A2 (en) 2025-12-24
UA127515C2 (uk) 2023-09-20
SV2018005634A (es) 2018-06-26
IL298041A (en) 2023-01-01
JP2025013894A (ja) 2025-01-28
TW201718651A (zh) 2017-06-01
HUE050556T2 (hu) 2020-12-28
US10072088B2 (en) 2018-09-11
RS60755B1 (sr) 2020-10-30
AU2016308567B2 (en) 2022-10-27
IL298041B1 (en) 2025-06-01
CA2995754A1 (en) 2017-02-23
TW202307000A (zh) 2023-02-16
NI201800027A (es) 2018-08-30
ECSP18019568A (es) 2018-04-30
PH12018500361A1 (en) 2018-09-03
UY36859A (es) 2017-04-28
HUS2300011I1 (hu) 2023-03-28
NL301219I2 (nl) 2023-04-04
FR23C1012I1 (fr) 2023-04-14
JP7621324B2 (ja) 2025-01-24
NZ739862A (en) 2025-05-02
PT3337824T (pt) 2020-09-10
LUC00301I2 (nl) 2025-09-22
PE20180795A1 (es) 2018-05-09
EP3337824A1 (en) 2018-06-27
TWI777924B (zh) 2022-09-21
CN108350076B (zh) 2022-06-07
CO2018001524A2 (es) 2018-07-10
EP3337824B1 (en) 2020-06-03
EA201890513A1 (ru) 2018-11-30
MA53750A (fr) 2021-09-15
HRP20201375T1 (hr) 2020-11-27
EP3757131A1 (en) 2020-12-30
PL3337824T3 (pl) 2021-04-19
MX2022006650A (es) 2022-07-05
KR102890745B1 (ko) 2025-11-26
CY2023007I1 (el) 2023-06-09
IL298041B2 (en) 2025-10-01
DK3337824T3 (da) 2020-08-24
LTPA2023509I1 (nl) 2023-03-10
KR20250007058A (ko) 2025-01-13
JO3799B1 (ar) 2021-01-31
JP2023027228A (ja) 2023-03-01
MY191325A (en) 2022-06-15
US20170051068A1 (en) 2017-02-23
IL257468A (en) 2018-04-30
MX2018002043A (es) 2018-07-06
UY40513A (es) 2023-11-30
CN108350076A (zh) 2018-07-31
IL257468B2 (en) 2023-06-01
CY2023007I2 (el) 2023-11-15
FR23C1011I1 (fr) 2023-04-14
TWI811023B (zh) 2023-08-01
CY1123297T1 (el) 2021-12-31
SI3337824T1 (sl) 2020-10-30
JP7194240B2 (ja) 2022-12-21
BR112018003017A2 (pt) 2018-09-25
WO2017031104A1 (en) 2017-02-23
CL2018000431A1 (es) 2018-11-23
ZA201801789B (en) 2019-10-30

Similar Documents

Publication Publication Date Title
NL301219I1 (nl)
AU2022228198B1 (nl)
BE2015C047I2 (nl)
BE2015C044I2 (nl)
BR0009942B1 (nl)
BR0000126B1 (nl)
BR0000695B1 (nl)
BR0000763F1 (nl)
BR0001536B1 (nl)
BR0001684B1 (nl)
BR0001810B1 (nl)
BR0002033B1 (nl)
BR0002402B1 (nl)
BR0002435B1 (nl)
BR0002694B1 (nl)
BR0002802B1 (nl)
BR0002874B1 (nl)
BR0003166B1 (nl)
BR0003189B1 (nl)
BR0017559B1 (nl)
BR0003401B1 (nl)
BR0003686B1 (nl)
BR0003746B1 (nl)
BR0003751B1 (nl)
BR0003928B1 (nl)